Comparative Pharmacology
Head-to-head clinical analysis: TOTACILLIN versus UTIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOTACILLIN versus UTIMOX.
TOTACILLIN vs UTIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
For UTIMOX (amoxicillin/clavulanate), typical adult dose is 875 mg/125 mg orally every 12 hours or 500 mg/125 mg orally every 8 hours, depending on infection severity.
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 8-12 hours in severe impairment (CrCl <30 mL/min).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Primarily renal (85-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic